| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥324.4B | ¥298.6B | +8.7% |
| Operating Income | ¥-23.6B | ¥6.2B | -59.4% |
| Ordinary Income | ¥-24.4B | ¥6.5B | -58.2% |
| Net Income | ¥-18.2B | ¥2.3B | -896.5% |
| ROE | -18.7% | 2.0% | - |
FY2026 Q2 results show revenue of 324.4B yen (YoY +8.7%) with operating loss of 23.6B yen (prior year operating income 6.2B yen, representing a swing of -29.8B yen). Ordinary loss reached 24.4B yen (YoY -58.2%) and net loss 18.2B yen (prior year net income 2.3B yen, deteriorating by -896.5%). Despite 8.7% revenue growth driven primarily by BToC segment expansion (+10.7%), profitability collapsed due to advertising expenses ballooning to 214.6B yen within SGA expenses of 286.6B yen (88.3% of revenue). Gross profit margin remained strong at 81.1%, but the company swung from profitability to substantial operating losses. This represents a critical inflection point with revenue growth decoupling from profit performance.
Revenue increased 25.8B yen to 324.4B yen (+8.7% YoY), driven primarily by BToC segment expansion. BToC revenue grew 28.7B yen (+10.7%), representing 88.6% of total revenue and serving as the primary growth engine. However, BToB segment contracted 4.9% to 35.8B yen, and BioMedical segment declined 23.0% to 1.0B yen. The revenue composition shows high concentration risk with BToC representing nearly 90% of sales.
On the profit side, operating income deteriorated sharply from 6.2B yen profit to 23.6B yen loss (a swing of -29.8B yen). The primary driver was SGA expense expansion to 286.6B yen (+26.6% YoY), with advertising expenses reaching 214.6B yen (+23.0% YoY). This represents 66.2% of total revenue, indicating an advertising-intensive business model that sacrificed short-term profitability. Commission fees within SGA increased to 26.5B yen from 20.4B yen, suggesting increased distribution costs. Despite gross profit increasing 8.4B yen, the 50.0B yen surge in SGA expenses overwhelmed gross profit growth. R&D expenses increased modestly to 6.9B yen (2.1% of revenue), up from 6.4B yen.
The gap between ordinary loss of 24.4B yen and operating loss of 23.6B yen reflects net non-operating expenses of 0.8B yen. Non-operating income of 1.7B yen (including dividend income 0.2B yen and equity method gains 0.2B yen) was offset by non-operating expenses of 2.4B yen (interest expense 0.6B yen, commission fees 1.5B yen). The gap between ordinary loss and net loss narrowed due to tax benefits of 7.3B yen and extraordinary losses of 1.2B yen (primarily loss on sale of subsidiary stock 0.1B yen), resulting in net loss of 18.2B yen.
This represents a revenue up/profit down pattern, where top-line growth failed to translate into bottom-line performance due to disproportionate SGA expense growth, particularly advertising investments.
BToC segment generated revenue of 287.3B yen (+10.7% YoY) but posted operating loss of 15.6B yen (prior year operating income 9.9B yen, representing a deterioration of -158.1%). Operating margin collapsed to -5.4% from +3.8%. As the core business accounting for 88.6% of total revenue, this segment's profitability crisis drives overall company performance. The segment's advertising-heavy strategy appears unsustainable given the margin erosion.
BToB segment produced revenue of 35.8B yen (-4.9% YoY) with operating income of 5.0B yen (-29.2% YoY). Operating margin remained positive at 14.0%, down from 18.9%, making this the only profitable segment. Despite revenue contraction, BToB maintains significantly superior margins compared to BToC, highlighting the efficiency differential between business models.
BioMedical segment recorded revenue of 1.0B yen (-23.0% YoY) with operating loss of 2.6B yen (margin -250.0%), representing ongoing investment phase with no path to profitability evident in current results. The segment's operating loss deepened from 2.0B yen, indicating continued cash consumption.
Other segments (fund operations) contributed minimal revenue of 0.3B yen with operating loss of 0.1B yen. Corporate expenses allocated across segments totaled 10.2B yen (including unallocated general administrative expenses 10.2B yen and goodwill amortization 0.2B yen), up from 8.6B yen prior year. The margin disparity between BToB (+14.0%) and BToC (-5.4%) represents a 19.4 percentage point gap, suggesting fundamental business model differences in profitability structure.
[Profitability] ROE of -18.7% reflects severe profit deterioration with negative return on equity. Operating margin of -7.3% (deteriorated from +2.1% YoY by -9.4pt) indicates cost structure misalignment with revenue growth. Gross profit margin maintained at 81.1% (down slightly from 81.3%) demonstrates product-level pricing power remains intact, but SGA ratio of 88.3% (up from 79.2% by +9.1pt) consumed all gross profit and more. [Cash Quality] Cash and deposits of 76.9B yen decreased from 91.6B yen, representing 0.55x coverage of short-term debt of 139.6B yen (short-term loans 139.0B yen plus current portion of long-term loans 0.6B yen), indicating liquidity pressure. [Investment Efficiency] Total asset turnover of 1.01x (annualized from H1 revenue) shows capital utilization efficiency maintained. Inventory increased to 77.3B yen from 63.1B yen (+22.5%), suggesting working capital deterioration and potential obsolescence risk. [Financial Health] Equity ratio of 30.3% declined from 35.4% (-5.1pt), approaching concerning leverage levels. Current ratio of 103.1% provides minimal liquidity cushion with quick ratio of 67.5% indicating dependence on inventory conversion. Debt-to-equity ratio of 2.30x (total interest-bearing debt 142.9B yen against equity 97.7B yen) represents elevated leverage with interest coverage turning negative due to operating losses.
Operating CF of -27.8B yen represents a dramatic deterioration from 0.2B yen positive in prior year, swinging -28.0B yen. This equates to 1.53x net loss of -18.2B yen, suggesting non-cash charges partially offset net loss, though operating activities still consumed significant cash. Subtotal operating CF before working capital changes was -14.6B yen, indicating core operations generated negative cash. Working capital movements consumed additional cash with inventory increase of 13.9B yen representing major outflow, partially offset by accounts receivable decrease of 6.8B yen. Income taxes paid of 14.3B yen (despite current year loss, likely prior year obligations) further strained operating cash. Investing CF of -5.4B yen comprised primarily CapEx of -4.7B yen, suggesting continued investment despite operating difficulties. FCF of -33.2B yen (operating CF -27.8B yen plus investing CF -5.4B yen) indicates severe cash consumption requiring external funding. Financing CF of 18.5B yen provided partial relief through net increase in short-term borrowings of 25.0B yen, offset by long-term debt repayment of -2.8B yen, dividend payments of -3.6B yen, and treasury stock disposal proceeds of 7.6B yen. Cash decreased 14.7B yen from 90.6B yen to 75.9B yen period-end. The CapEx to depreciation ratio of 1.44x (4.7B yen capex versus 3.3B yen D&A) indicates growth investment continues, though sustainability is questionable given negative FCF.
Ordinary loss of 24.4B yen versus operating loss of 23.6B yen shows net non-operating expense contribution of approximately 0.8B yen. Non-operating income represents 0.5% of revenue at 1.7B yen, consisting primarily of dividend income 0.2B yen and equity method gains 0.2B yen, indicating limited non-core income contribution. Non-operating expenses of 2.4B yen included interest expense 0.6B yen (indicating relatively modest interest burden given 142.9B yen debt) and commission fees 1.5B yen. The alignment between operating and ordinary losses suggests core business operations drive overall performance without material non-operating distortions. Extraordinary losses of 1.2B yen (primarily loss on subsidiary stock sale 0.1B yen) represent non-recurring factors. Comprehensive income of -16.0B yen exceeded net loss of -18.2B yen by 2.2B yen due to valuation gains on securities (OCI +2.3B yen), suggesting unrealized investment gains partially offset realized losses. Operating CF of -27.8B yen being more negative than net loss indicates accrual-basis earnings quality concerns, with cash realization significantly lagging reported losses due to working capital deterioration, particularly inventory accumulation of 13.9B yen. The inventory buildup combined with advertising expense surge suggests potential channel stuffing or demand-supply mismatch requiring monitoring.
Full-year guidance projects revenue of 670.0B yen (YoY +2.7%), operating income of 20.0B yen (YoY -15.5%), and ordinary income of 20.0B yen (YoY -21.7%). H1 progress rates show revenue achievement of 48.5% (324.4B yen / 670.0B yen), slightly below standard 50% midpoint, suggesting modest H2 acceleration required. However, operating income shows -118.1% achievement (operating loss of 23.6B yen against full-year profit target of 20.0B yen), indicating management expects dramatic H2 turnaround of approximately 43.6B yen improvement. This implies H2 operating margin must reach approximately 12.6% on H2 revenue of approximately 345.6B yen, representing an unprecedented swing from H1's -7.3% margin. The guidance was revised during Q2, though specific revision magnitude is not detailed. Forecast notes indicate business outlook contains significant uncertainty regarding achievement of advertising efficiency and cost control measures necessary for H2 profitability recovery. Given H1's severe SGA expense overrun (286.6B yen representing 88.3% of revenue), achieving full-year operating profit of 20.0B yen requires either substantial advertising spending reduction in H2 or dramatic revenue acceleration with operating leverage. The 48.5% revenue progress versus -118.1% operating income progress represents a 166.6 percentage point gap, signaling execution risk on profitability guidance. No order backlog data is available to assess forward revenue visibility.
Annual dividend of 12.5 yen per share is maintained, unchanged from prior year. Q2 dividend of 12.5 yen was paid. Based on net loss of 18.2B yen and approximately 29.1 million shares outstanding, the calculated payout ratio is negative at approximately -19.9% (calculated as 12.5 yen * 29.1M shares / -18.2B yen net loss), indicating dividend payments exceed earnings and are funded through retained earnings or external financing. Against FCF of -33.2B yen, dividend payments of approximately 3.6B yen represent -10.9% FCF coverage, confirming dividends are not sustainable from operating cash generation. No share buyback activity is reported for the period, though treasury stock decreased from 1.95B yen to 0.26B yen, suggesting treasury stock disposal of approximately 1.7B yen occurred (confirmed by disposal proceeds of 7.6B yen in financing CF), likely for capital/liquidity purposes rather than shareholder returns. The total return ratio combining dividends and buybacks cannot be calculated as buybacks were negative (stock disposal). Dividend sustainability is highly questionable given both earnings and cash flow are negative, though management has not revised dividend forecast, suggesting commitment to shareholder returns despite financial stress. Maintaining dividends at 12.5 yen while posting net losses and negative FCF indicates reliance on balance sheet cash reserves of 76.9B yen, which have declined 14.7B yen during H1, raising concerns about medium-term dividend policy viability without operational improvement.
Revenue concentration in BToC segment at 88.6% of total sales creates significant business model risk, as consumer demand volatility, competitive promotional pressures, or channel disruption could materially impact overall performance. The segment's operating loss of 15.6B yen indicates this concentration currently drives negative profitability. Advertising dependency risk is quantified with 214.6B yen advertising spend representing 66.2% of revenue, indicating business model relies on sustained high marketing investment to drive sales. If advertising effectiveness diminishes or budget constraints force reductions, revenue generation capacity could collapse. The 23.0% YoY advertising expense growth outpacing 8.7% revenue growth suggests deteriorating return on advertising spend. Liquidity and refinancing risk stems from short-term debt concentration with 139.0B yen short-term loans representing 97.3% of total interest-bearing debt of 142.9B yen, while cash coverage stands at only 0.55x and operating CF is negative 27.8B yen. This maturity mismatch creates refinancing pressure, and any credit tightening or lender reluctance could trigger funding crisis, particularly given negative profitability reducing creditworthiness.
[Industry Position] (Reference - Proprietary Analysis)
The company's FY2026 Q2 financial metrics show significant underperformance relative to historical baselines. Operating margin of -7.3% represents severe deterioration from normalized profitability levels, driven by SGA expense ratio of 88.3% that exceeds revenue generation capacity. While gross profit margin of 81.1% indicates strong product-level economics comparable to premium consumer goods positioning, the advertising-intensive business model with advertising representing 66.2% of revenue creates profitability structure misalignment.
Equity ratio of 30.3% has declined toward concerning leverage territory, with debt-to-equity of 2.30x exceeding prudent leverage thresholds typically observed in stable consumer goods businesses. The liquidity profile with current ratio of 103.1% and cash coverage of short-term debt at 0.55x suggests financial flexibility constraints relative to industry norms where stronger balance sheets typically maintain current ratios above 150% and cash/short-term debt ratios exceeding 1.0x.
ROE of -18.7% reflects temporary profitability crisis, as negative returns indicate value destruction. Historical company performance suggests normalized ROE in positive mid-single digits when profitability stabilizes. The company's revenue growth of 8.7% maintains market position expansion, though profit conversion failure distinguishes current performance from sustainable growth patterns.
Limited benchmark data availability constrains precise industry peer comparison, though the advertising spend intensity and negative operating leverage represent structural concerns requiring management intervention regardless of peer positioning.
Revenue growth persistence at 8.7% demonstrates continued market acceptance and distribution expansion, particularly within core BToC channel growing 10.7%, indicating brand strength and customer acquisition capability remain intact despite profitability challenges. However, the advertising expense surge to 214.6B yen (66.2% of revenue) represents unsustainable economics requiring structural correction. The fact that gross profit margin maintained at 81.1% while operating margin collapsed to -7.3% isolates SGA efficiency as the critical operational issue rather than product competitiveness or pricing pressure.
Inventory accumulation to 77.3B yen (+22.5% YoY) combined with negative operating cash flow of -27.8B yen signals working capital management deterioration and potential demand-supply mismatch. The 13.9B yen inventory increase consuming operating cash while advertising spending accelerated suggests possible channel stuffing or promotional inventory buildup to support aggressive marketing campaigns. This pattern warrants close monitoring for inventory obsolescence risk and subsequent markdown pressure.
Short-term debt reliance at 97.3% of total interest-bearing debt with declining cash position (down 14.7B yen to 76.9B yen) creates refinancing dependency requiring operational cash flow recovery for financial stability. The company's maintenance of 12.5 yen dividend despite negative earnings and FCF demonstrates shareholder return commitment but strains already-pressured liquidity. Management's full-year guidance implying dramatic H2 recovery (requiring approximately 43.6B yen operating income improvement) represents ambitious turnaround assumption requiring verification through Q3/Q4 performance trends.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.